No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, and extended-duration GLP-1 receptor agonists, specifically targeting the treatment of diabetes and other metabolic conditions.
www.innogenpharm.comNo one on the platform currently holds 2591.HK.
No tracked institution reports a position in 2591.HK as of their last filing.
No one on the platform has traded 2591.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | ||||||
| Profit Margin % | -259.6% | |||||
| Free Cash Flow Margin % | -247.9% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $395M | +185.6% | $-0.51 | $-0.62–$-0.41 | — | 2 |
| 2027 | $942M | +138.4% | $-0.06 | $-0.12–$0.00 | — | 2 |
| 2028 | $1.5B | +54.2% | $0.27 | $0.17–$0.38 | — | 1 |
| 2029 | $3.4B | +133.3% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $3.98 |
| +0.00% |
| $7.2B |
| — |
| 2162.HKKeymed Biosciences Inc. | $74.60 | -0.47% | $22.0B | — |
| 2315.HKBiocytogen Pharmaceuticals (Beijing) Co., Ltd. | $57.00 | -4.12% | $23.1B | — |
Source: Financial Modeling Prep · peers by sector/industry